0
0
BioNTech’s precision breast cancer drug, developed in partnership with Chinese biotech Duality Biologics, recently achieved a significant milestone by meeting its primary goal in a crucial late-stage clinical trial, marking a hopeful advance for patients and the future of oncology treatment.
Trial Success Heralds Potential New Breast Cancer Therapy
On September 5, 2025, BioNTech and Duality Biologics announced that their investigational antibody-drug conjugate (ADC) therapy, trastuzumab pamirtecan (also known as BNT323 or DB-1303), succeeded in a Phase III trial conducted in China. This trial focused on patients with HER2-positive advanced breast cancer that was unresectable or metastatic and who had previously undergone established treatments such as trastuzumab and taxane chemotherapy. The primary endpoint of the trial was progression-free survival (PFS), measured by an independent review, and the trial showed a significant improvement in PFS compared to Roche’s widely used ADC therapy Kadcyla (trastuzumab emtansine).
Understanding the Therapy and Trial Context
Antibody-drug conjugates like trastuzumab pamirtecan combine the targeting capabilities of monoclonal antibodies with potent cancer-killing drugs, delivering chemotherapy directly to tumor cells while sparing healthy tissue. Trastuzumab pamirtecan links trastuzumab—an antibody targeting HER2 receptors on cancer cells—to a topoisomerase I inhibitor, a type of chemotherapy agent. This design is similar to AstraZeneca and Daiichi Sankyo’s Enhertu, an ADC already approved for certain HER2-positive breast cancers and well-regarded for extending progression-free survival.
The trial enrolled 228 breast cancer patients in China and randomly assigned them to receive either trastuzumab pamirtecan or Kadcyla. The patient population included those with HER2-positive cancers that were resistant to surgery and prior drug treatments, a group representing significant clinical need. Early analysis showed that patients receiving BioNTech and Duality’s drug were less likely to experience cancer progression or death at this interim point, striking a notable improvement over Kadcyla.
Expert Perspectives on the Findings
Özlem Türeci, MD, Chief Medical Officer and co-founder of BioNTech, highlighted the trial’s success as an important milestone in the company’s oncology ambitions, calling trastuzumab pamirtecan “an ADC candidate with enormous potential.” She emphasized the therapeutic’s role within BioNTech’s global oncology strategy, which includes combining it with other treatments to increase efficacy.
Duality Biologics’ Global Medical Officer, Dr. Hua Mu, underscored the significance of the study for regulatory discussions in China and plans for broader commercialization in the U.S. and Europe. The partners have initiated a global Phase III trial named DYNASTY-Breast-02 to evaluate the drug in wider HER2-positive breast cancer populations, with results expected in 2026.
Broader Implications for Public Health and Oncology
The trial’s results are promising for breast cancer patients facing limited options after standard treatments fail to control disease progression. HER2-positive breast cancer, characterized by an overexpression of the HER2 receptor that drives tumor growth, benefits from targeted therapies such as trastuzumab (Herceptin) and ADCs like Kadcyla and now potentially trastuzumab pamirtecan. Improved progression-free survival can translate into extended periods of quality life for patients.
From a public health perspective, this development may expand treatment choices and potentially improve survival outcomes for a large subset of breast cancer patients globally. Since breast cancer remains one of the leading causes of cancer-related deaths among women worldwide, innovations that slow disease progression are critical.
Potential Limitations and Considerations
While the trial outcome is encouraging, several factors warrant cautious interpretation. The results are based on an interim analysis rather than complete data, and detailed statistical metrics—such as exact hazard ratios and overall survival data—have yet to be fully disclosed. Additionally, trastuzumab pamirtecan’s chemical similarity to Enhertu, a drug known to carry more side effects relative to Kadcyla, suggests that this new treatment might also bring increased adverse effects. Clinical management and patient monitoring will be essential to balance benefits against risks.
Regulatory approval processes in China, the U.S., and Europe will require comprehensive review of safety and efficacy data. Furthermore, the global applicability beyond the Chinese population studied will need evaluation, considering genetic diversity and variable health system contexts.
Practical Advice for Readers
For individuals diagnosed with HER2-positive breast cancer or caretakers, these findings represent hopeful news. However, it is important to understand that trastuzumab pamirtecan is still undergoing trials and regulatory review and is not yet a standard therapy. Patients should continue following the guidance of oncology specialists and keep abreast of emerging treatment options. For the broader public, maintaining awareness of advances in targeted cancer therapies contributes to informed health decisions and supports advocacy for access to novel treatments.
Conclusion
BioNTech and Duality Biologics’ breakthrough in their Phase III trial of a precision ADC therapy against HER2-positive breast cancer stands as a testament to the innovation potential in oncology beyond infectious diseases like COVID-19. As this treatment progresses toward regulatory review, it offers promise for improved care options and renewed hope for patients confronting challenging breast cancer types.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
BioNTech and Duality achieve primary endpoint in Phase III trial of trastuzumab pamirtecan in HER2-positive advanced breast cancer, Inside Precision Medicine, September 4, 2025.
